Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC318 in Advanced or Metastatic Solid Tumors
NCT03665285Phase 2Completed
- Sponsor
- NextCure, Inc.
- Start
- Oct 2018
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nc318 in solid tumor (advanced stage), metastatic solid tumors, lung cancer, breast cancer, head and neck squamous cell carcinoma (HNSCC), sponsored by NextCure, Inc.. Started Oct 2018; status: completed.
02
Drugs
nc318
03
Conditions
solid tumor (advanced stage)metastatic solid tumorslung cancerbreast cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03665285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665285.